Carlsmed, Inc. (NASDAQ:CARL) Given Consensus Rating of “Hold” by Analysts

Shares of Carlsmed, Inc. (NASDAQ:CARL) have received an average recommendation of “Hold” from the five analysts that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $19.6667.

A number of equities research analysts recently weighed in on the stock. The Goldman Sachs Group lowered their target price on shares of Carlsmed from $19.00 to $17.00 and set a “buy” rating on the stock in a research note on Thursday, April 9th. Weiss Ratings reaffirmed a “sell (e-)” rating on shares of Carlsmed in a research note on Monday, December 22nd. Zacks Research raised shares of Carlsmed from a “strong sell” rating to a “hold” rating in a research note on Thursday, March 26th. Wall Street Zen raised shares of Carlsmed from a “sell” rating to a “hold” rating in a research note on Saturday, February 14th. Finally, Truist Financial lowered their target price on shares of Carlsmed from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday.

Institutional Investors Weigh In On Carlsmed

Institutional investors and hedge funds have recently bought and sold shares of the stock. TD Waterhouse Canada Inc. purchased a new stake in Carlsmed in the third quarter valued at approximately $2,026,000. Teacher Retirement System of Texas purchased a new stake in Carlsmed in the third quarter valued at approximately $2,343,000. Monashee Investment Management LLC purchased a new stake in Carlsmed in the third quarter valued at approximately $536,000. Ghisallo Capital Management LLC bought a new position in Carlsmed during the third quarter valued at approximately $670,000. Finally, Kornitzer Capital Management Inc. KS bought a new position in Carlsmed during the third quarter valued at approximately $736,000.

Carlsmed Trading Up 2.8%

Shares of Carlsmed stock opened at $10.98 on Friday. Carlsmed has a 12-month low of $8.50 and a 12-month high of $17.19. The company has a market cap of $293.50 million and a price-to-earnings ratio of -3.00. The company has a current ratio of 8.87, a quick ratio of 8.74 and a debt-to-equity ratio of 0.16. The company’s 50-day moving average price is $11.20 and its 200-day moving average price is $12.49.

Carlsmed (NASDAQ:CARL) last announced its quarterly earnings results on Wednesday, February 25th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.11. Carlsmed had a negative net margin of 58.67% and a negative return on equity of 72.60%. The firm had revenue of $15.16 million for the quarter, compared to the consensus estimate of $15.20 million.

Carlsmed Company Profile

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).